Takeda, the Longest-Standing Corporate Partner of the Global Fund, Pledges to the Eighth Replenishment
20 May 2025
GENEVA – The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) welcomed a commitment of JPY 350 million from Takeda Pharmaceutical Company, a Japan-based global leader in pharmaceuticals. This marks the first corporate commitment to the Global Fund’s Eighth Replenishment.
Takeda is one of the longest standing supporters of the Global Fund. This new contribution for a two-year program will build upon the Takeda Initiative — a 15-year, JPY 2 billion philanthropic partnership aimed at improving maternal and child health by integrating HIV, tuberculosis (TB), and malaria services into antenatal and postnatal care (ANC/PNC) in Kenya, Nigeria and Tanzania. Such integration is crucial in promoting early detection and treatment, leading to healthier pregnancies and better long-term health outcomes for both mothers and their babies. Over the past five years, the Takeda Initiative has supported 1.5 million mothers in receiving quality care. Building on this success, the renewed partnership will support the scale and sustainability of the integrated care model.
Since 2010, Takeda has been one of the Global Fund’s most dedicated corporate partners — the longest-running to date — providing vital support for disease prevention and health system strengthening across sub-Saharan Africa. Its contributions have included support to scale up malaria prevention in Tanzania through the distribution of mosquito nets, expanded access to TB treatment in Kenya, and enhanced HIV services and awareness in Nigeria, with a focus on integrating these efforts into ANC/PNC for improved service delivery.
“For over 240 years, Takeda has prioritized patients and thoughtfully contributed to societal impact. Our long-standing collaboration with the Global Fund reflects this deeply rooted commitment,” said Takako Ohyabu, Chief Global Corporate Affairs and Sustainability Officer at Takeda Pharmaceutical Company. “Through the Takeda Initiative, we have advanced systemic improvements in health care delivery for mothers and children in sub-Saharan Africa. With this renewed pledge, we remain committed to sustaining and scaling this impact by empowering local leadership and the health workforce for resilient health systems. Our contribution underscores the vital role of the private sector in tackling global health challenges and driving lasting change, in close collaboration with stakeholders.”
“The Takeda Initiative has demonstrated how innovation, commitment and local ownership can transform health systems and improve lives — offering a powerful model for other corporate donors,” said Peter Sands, Executive Director of the Global Fund. “We are deeply grateful to Takeda and call on corporate leaders and philanthropists to join us in supporting the Global Fund’s Eighth Replenishment. Together, we can turn scientific breakthroughs into scalable solutions that protect the most vulnerable, strengthen health systems and build a healthier world for generations to come.”
With an ambitious goal of raising US$2 billion from private donors for its Eighth Replenishment, the Global Fund is recognizing and elevating the role of the private sector as a transformative force in global health. Every dollar invested delivers an estimated US$19 in health gains and economic returns, creating lasting benefits. By leveraging private capital and innovation, the Global Fund is shaping high-impact, sustainable solutions that can transform public health worldwide.